SDC1 and plasma cell myeloma: BT062 (indatuximab ravtansine), an anti-CD138 IgG4 antibody with a wild type hinge region and conjugated to the tubulin inhibiting agent DM4 was able to demonstrate anti-tumor efficacies for multiple myeloma in preclinical experiments [18,33].